|Day Low/High||133.45 / 136.65|
|52 Wk Low/High||105.19 / 220.10|
SAN DIEGO, Nov. 8, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc.
SAN DIEGO and CAMBRIDGE, Mass. and BEIJING, Oct.
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, a...
The biopharmaceutical giant's top executive says the company will continue to aggressively invest in R&D and deploy capital to acquire or license assets.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.